Blood clot risk prompts suspension of sales of Iclusig

Ariad's Iclusig, or ponatinib, has been pulled from the market less than a year after it was approved for the treatment of chronic myeloid leukemia due to the risk of blood clots, according to the FDA. The agency and Ariad will work to identify patients who can be helped by the drug, and the withdrawal is not considered permanent.

View Full Article in:

New York Times (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID